Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

Phase I trial of the novel epothilone sagopilone (ZK-EPO) in combination with cisplatin as first-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)

(2017) T. C. Gauler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of sagopilone (ZK-EPO), a novel epothilone, in patients with metastatic melanoma

(2017) D. Wenk et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

(2011) K. N. Chi et al.   ANNALS OF ONCOLOGY

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors

(2009) P. Schmid et al.   ANNALS OF ONCOLOGY

Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer

(2009) Trine Zeeberg Buch-Hansen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer

(2008) A. Hussain et al.   ANNALS OF ONCOLOGY

Improved Cellular Pharmacokinetics and Pharmacodynamics Underlie the Wide Anticancer Activity of Sagopilone

(2008) J. Hoffmann et al.   CANCER RESEARCH